| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 14/01/2025 | 01:05 | UK Regulatory | FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease | LSE:0R1B | Biogen Inc |
| 19/11/2024 | 07:00 | UK Regulatory | Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity | LSE:0R1B | Biogen Inc |
| 14/11/2024 | 17:23 | UK Regulatory | Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease | LSE:0R1B | Biogen Inc |
| 31/10/2024 | 00:30 | UK Regulatory | Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference | LSE:0R1B | Biogen Inc |
| 29/10/2024 | 23:00 | UK Regulatory | Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases | LSE:0R1B | Biogen Inc |
| 29/10/2024 | 13:00 | UK Regulatory | Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer | LSE:0R1B | Biogen Inc |
| 28/10/2024 | 13:30 | UK Regulatory | Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025 | LSE:0R1B | Biogen Inc |
| 27/10/2024 | 02:15 | UK Regulatory | Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024 | LSE:0R1B | Biogen Inc |
| 24/10/2024 | 13:30 | UK Regulatory | Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference | LSE:0R1B | Biogen Inc |
| 22/10/2024 | 13:30 | UK Regulatory | Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024 | LSE:0R1B | Biogen Inc |
| 09/10/2024 | 13:30 | UK Regulatory | Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients | LSE:0R1B | Biogen Inc |
| 08/10/2024 | 13:30 | UK Regulatory | New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA | LSE:0R1B | Biogen Inc |
| 24/09/2024 | 07:00 | UK Regulatory | UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024 | LSE:0R1B | Biogen Inc |
| 12/09/2024 | 13:30 | UK Regulatory | Biogen Board Appoints Two New Independent Directors | LSE:0R1B | Biogen Inc |
| 04/09/2024 | 13:30 | UK Regulatory | Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA | LSE:0R1B | Biogen Inc |
| 30/07/2024 | 23:15 | UK Regulatory | New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC | LSE:0R1B | Biogen Inc |
| 30/07/2024 | 13:30 | UK Regulatory | Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease | LSE:0R1B | Biogen Inc |
| 26/07/2024 | 13:20 | UK Regulatory | Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union | LSE:0R1B | Biogen Inc |
| 06/03/2024 | 13:30 | UK Regulatory | New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy | LSE:0R1B | Biogen Inc |
| 04/03/2024 | 22:15 | UK Regulatory | Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting | LSE:0R1B | Biogen Inc |
| 23/02/2024 | 13:00 | UK Regulatory | Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP | LSE:0R1B | Biogen Inc |
| 12/02/2024 | 22:06 | UK Regulatory | Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia | LSE:0R1B | Biogen Inc |
| 31/01/2024 | 13:30 | UK Regulatory | Biogen to Realign Resources for Alzheimer's Disease Franchise | LSE:0R1B | Biogen Inc |
| 06/08/2023 | 18:07 | Alliance News |  CORRECT: Biogens, Sage Therapeutics postpartum depression drug okayed | LSE:0R1B | Biogen Inc |
| 06/08/2023 | 15:17 | Alliance News | Biogens, Sage Therapeutics postpartum depression treatment approved | LSE:0R1B | Biogen Inc |
| 09/06/2023 | 13:12 | Alliance News | *Nasdaq halts trading of Biogen stock | LSE:0R1B | Biogen Inc |
| 13/01/2020 | 15:28 | Alliance News | Pfizer Could Net USD635 Million As Biogen Acquires Alzheimer's Drug | LSE:0R1B | Biogen Inc |